Los Angeles, California
Check us out on Twitter!
PIH Health Good Samaritan Hospital
Los Angeles, CA
CALIFORNIA CHAPTER OF THE
AMERICAN COLLEGE OF CARDIOLOGY
INTERNATIONAL ACADEMY OF CARDIOLOGY
An Update on Therapy
March 12 & 13, 2021
IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed.
Surveys are accessible after signing in with the email address you submitted during registration.
Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by April 5, 2021 in order to receive your certificate. Certificates will be available online until November 1, 2021 and are printable directly from the website.
The AAFP Credit System and the Commission on Continuing Professional Development (COCPD) would like to thank you for applying for AAFP CME credit. Your activity has been approved for AAFP CME credit. Announcement of AAFP credit for the activity must be presented exactly as follows:
The AAFP has reviewed 25th Annual Heart Failure 2021: An Update on Therapy and deemed it acceptable for up to 8.5 Online Only, Live AAFP Prescribed credit. Term of Approval is from 03/12/2021 to 03/13/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approval for AAFP CME credit does not imply authorization to use the AAFP logo on CME activity materials or to use AAFP's name in any association with the activity other than the credit statement.
The AAFP reserves the right to perform a post - activity audit and / or have a live monitor at any AAFP certified CME activity.
AMA / AAFP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
This year's virtual symposium provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts in their field. The extensive list of topics has been selected to provide a high level, contemporary and clinically relevant update with a goal of improving the care of patients with heart failure
At the conclusion of this activity, the participants should be able to:
- Review recent guidelines for the management of HF.
- Manage volume overload in hospitalized patients with HF and review new
recommendations for the use of diuretics.
- Learn how to use SGLT2 inhibitors in the treatment of HF.
- Review the effects and role of the new drugs vericiguat and Omecamptiv in
the management of HF.
- Provide an update on the diagnosis and management of various cardiomyopathies.
- Review new technologies for the management of mitral and
- Understand the role of genetic testing in patients with cardiomyopathies.
- Review the definition, outcome and management of patients with recovered
- Review the innovations in the area of ventricular assist devices in the
management of advanced HF.
- Review innovations in the use of new devices for the treatment of acute
decompensated heart failure.
- Discuss the use of biomarkers for the diagnosis and management of heart failure.
- Discuss the approach for the diagnosis and management of heart failure with
preserved ejection fraction.
- Discuss the role of artificial intelligence to diagnose and manage heart failure.
- Discuss the hemodynamic and clinical effect of inter atrial shunt in the
treatment of heart failure.
- Review the recent real- world experience with remote hemodynamic
monitoring for the prevention of hospitalizations.
- Discuss the importance of equity in medicine.
- Review the effect of race on the outcome of heart failure.
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
Heart failure (HF) is common, but often unrecognized and misdiagnosed. Early diagnosis and effective therapy is important (Circulation 2013;128:e240).There is strong evidence that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (BMC CV Disorders 2016;16:195). Recent data continues to show an important gap between published guideline recommendations and practice (Eur J HF 2017;19:301) and demonstrates that life-saving drugs and devices are underutilized (Circulation 2016;133:273, JAMA Cardiol 2017;2561, JACC 2016: 67:1062) and indicates the need for education and incorporation of recent guidelines by clinicians (Circulation 2017;136:e137). Recently approved drugs for the management of heart failure provide a great opportunity for improved outcome and need to be incorporated into the care of patients with heart failure. Innovations in the diagnosis and management of various cardiomyopathies need to be embraced by clinicians for the benefit of the patients. The Heart Failure 2021 symposium has been designed to provide a comprehensive update on many of the new diagnostic and therapeutic modalities as well as information on new practice guidelines for the management of patients with HF.
It is our policy to ensure balance, independence, objectivity and scientific
rigor. All persons involved in the selection, development and presentation
of content are required to disclose any real or apparent conflicts of
interest. All conflicts of interest will be resolved prior to an educational
activity being delivered to learners through one of the following mechanisms
1) altering the financial relationship with the commercial interest, 2)
altering the individual’s control over CME content about the products
or services of the commercial interest, and/or 3) validating the activity
content through independent peer review. All persons are also required
to disclose any discussions of off label/unapproved uses of drugs or devices.
Persons who refuse or fail to disclose are disqualified from participating
in the CME activity. Participants will be asked to evaluate whether the
speaker’s outside interests reflect a possible bias in the planning
or presentation of the activity. This information is used to plan future